AstraZeneca's Phase III CASPIAN trial final analysis shows Imfinzi confirmed survival benefit for small cell lung cancer patients Medical Dialogues Bureau21 March 2020 9:00 AM ISTImfinzi confirmed a sustained overall survival benefit in the final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage small cell...
AstraZeneca fails to meet target endpoints in Phase II bladder cancer trial Medical Dialogues Bureau10 March 2020 9:30 AM ISTUSA: The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not...
AstraZeneca leukemia drug Calquence gets USFDA okay Medical Dialogues Bureau24 Nov 2019 10:00 AM ISTNew Delhi: AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go-ahead for the company's Calquence drug...
Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial Ruby Khatun Khatun1 Dec 2017 9:30 AM ISTFRANKFURT: Germany's Merck KGaA has suffered a setback in the development of key cancer immunotherapy Bavencio, it has failed in a trial to prolong...
AstraZeneca rebuilds cancer drug hopes with new lung data Ruby Khatun Khatun12 Sept 2017 9:32 AM ISTMADRID: Two AstraZeneca drugs tackling lung cancer in different ways delivered encouraging results on Saturday, helping the British group offset...